Lumos Diagnostics HoldingsASX:LDX -6.67% Return-on-Tangible-Asset is -74.28% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 84.43% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lumos Diagnostics Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-14.69 Mil. Lumos Diagnostics Holdings's average total tangible assets for the quarter that ended in Dec. 2025 was A$19.77 Mil. Therefore, Lumos Diagnostics Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -74.28%.
The historical rank and industry rank for Lumos Diagnostics Holdings's Return-on-Tangible-Asset or its related term are showing as below:
ASX:LDX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -187.29 Med: -51.65 Max: -47.41
Current: -61.99
During the past 4 years, Lumos Diagnostics Holdings's highest Return-on-Tangible-Asset was -47.41%. The lowest was -187.29%. And the median was -51.65%.
ASX:LDX's Return-on-Tangible-Asset is ranked worse than 84.43% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs ASX:LDX: -61.99
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Lumos Diagnostics Holdings Return-on-Tangible-Asset Related Terms
Lumos Diagnostics Holdings Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LDX vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -74.28% mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Return-on-Tangible-Asset of -74.28% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lumos Diagnostics Holdings and its competitors. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #721 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 84.4%.
Is Lumos Diagnostics Holdings' Return-on-Tangible-Asset too high?
Lumos Diagnostics Holdings' current Return-on-Tangible-Asset is -74.28%. Based on the distribution chart, Lumos Diagnostics Holdings ranks #721 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Lumos Diagnostics Holdings' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #721 out of 854 companies for Return-on-Tangible-Asset. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Return-on-Tangible-Asset is -74.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.10 — trading 390% above its estimated fair value. The current Return-on-Tangible-Asset is -74.28%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Return-on-Tangible-Asset is -74.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 